Enteral Lipid Supplementation and Bronchoplumonary Dysplasia of Premature Infants

ConditionBronchopulmonary Dysplasia (BPD)

Trial statusRecruiting

Trial phasePhase 4

Trial typeInterventional

Biological sexAll

Age24-29

SponsorAristotle University Of Thessaloniki

About this trial

The Impact of Omega-3 (DHA - Docosahexaenoic Acid) and Omega-6 (ARA - Arachidonic Acid) Supplementation on the Development of Bronchopulmonary Dysplasia in Extremely and Very Preterm Infants (24-29 weeks of gestational age).

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

Enteral supplementation with ARA and DHA (in a 2:1 ratio) in addition to standard care and feeding
Standard care and feeding

Treatment groups

74 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Aristotle University Of Thessaloniki

Lead sponsor

Source ClinicalTrials.gov